


Page 120, line 17, insert --- after "hydroxyethyl".

**IN THE CLAIMS**

Please cancel Claims 10-12 without prejudice.

1. (Amended) A compound of formula (I)



wherein:

R<sup>1</sup> is a C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> [alkenyl] alkynyl, C<sub>3-8</sub>-cycloalkyl or a phenyl group, each group being optionally substituted by one or more substituents selected from halogen, OR<sup>8</sup>, NR<sup>9</sup>R<sup>10</sup>, SR<sup>11</sup> or C<sub>1-6</sub> alkyl (itself optionally substituted by one or more halogen atoms);

R<sup>2</sup> is C<sub>1-8</sub> alkyl optionally substituted by one or more substituents selected from the group consisting of halogen, OR<sup>8</sup>, NR<sup>9</sup>R<sup>10</sup>, SR<sup>11</sup>, C<sub>3-8</sub>-cycloalkyl, aryl (optionally substituted by one or more C<sub>1-6</sub> alkyl groups and/or halogen atoms), [or] and C<sub>1-6</sub>-alkyl;

or R<sup>2</sup> is a C<sub>3-8</sub>-cycloalkyl group optionally substituted by one or more substituents

B

selected from the group consisting of halogen,  $OR^8$ ,  $NR^9R^{10}$ ,  $SR^{11}$ ,  $C_{1-6}$ -alkyl [or] and phenyl, the latter two groups being optionally substituted by one or more substituents selected from the group consisting of halogen,  $NO_2$ ,  $C(O)R^8$ ,  $OR^8$ ,  $SR^{11}$ ,  $NR^{12}R^{13}$ , [a fused 5- or 6-membered saturated ring containing one or two oxygen atoms,] 1,3-benzodioxolyl, phenyl [or] and  $C_{1-6}$ -alkyl the latter two groups being optionally substituted by  $OR^8$ ,  $NR^9R^{10}$  or one or more halogen atoms; one of  $R^3$  and  $R^4$  hydroxy and the other is hydrogen, hydroxy or  $N^9R^{10}$ ;

B4 R is a group  $(CR^5R^6)_mOR^7$  where m is 0 or 1,  $R^5$  and  $R^6$  are independently hydrogen,  $C_{1-6}$  alkyl or phenyl the latter two groups being optionally substituted by halogen, and  $R^7$  is hydrogen,  $C_{1-6}$  alkyl or  $(CR^5R^6)_nR^{14}$  where  $R^5$  and  $R^6$  are as defined above, n is 1 to 3 and  $R^{14}$  is  $COOH$ ,  $OR^{15}$ ,  $NR^{16}R^{17}$  or  $CONR^{16}R^{17}$ ; or R is a  $C_{1-4}$  alkyl or  $C_{2-4}$  alkenyl group, each of which is substituted by one or more groups selected from the group consisting of  $=S$ ,  $=O$ ,  $=NR^{20}$  [or] and  $OR^{21}$  and optionally substituted by one or more groups selected from the group consisting of halogen,  $C_{1-4}$  alkyl, phenyl,  $SR^{21}$ ,  $NO_2$  [or] and  $NR^{22}R^{23}$  (where  $R^{21}$ ,  $R^{22}$  and  $R^{23}$  are independently hydrogen,  $C_{1-4}$  alkyl or phenyl;  $R^{20}$  is  $OR^{24}$  or  $NR^{25}R^{26}$  where  $R^{24}$  is hydrogen,  $C_{1-4}$  alkyl or phenyl, and  $R^{25}$  and  $R^{26}$  are independently hydrogen,  $C_{1-4}$  alkyl, aryl,  $C_{1-6}$  acyl, arylsulphonyl or arylcarbonyl);  $R^8$  is hydrogen,  $C_{1-6}$  alkyl optionally substituted by halogen or  $R^8$  is phenyl optionally substituted by one or more substituents selected from halogen,  $NO_2$ ,  $C(O)R^6$ ,  $OR^6$ ,  $SR^9$ ,  $NR^{10}R^{11}$ ;  $R^9$ ,  $R^{10}$  and  $R^{11}$  are independently hydrogen or  $C_{1-6}$  alkyl;

R<sup>12</sup> and R<sup>13</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> acyl, C<sub>1-6</sub> alkyl sulfonyl optionally substituted by halogen, or phenyl sulfonyl optionally substituted by C<sub>1-</sub>

B4 C<sub>4</sub> alkyl; and

R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> are independently hydrogen or C<sub>1-6</sub> alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

Claim 2, line 1, insert --as defined in claim 1" after "(I)".

Claim 4, line 3, delete "C<sub>3-8</sub> and replace by --C<sub>1-6</sub>--.

Claim 8, page 131, line 31, delete "phenoyphenyl" and replace by --phenoxyphenyl--.

Page 136, line 7, delete "Dimethylphenyl" and replace by --Dimethylaminophenyl--;

lines 19-21, delete in their entirety.

Page 137, line 35, insert --)-- after "hydroxyethyl".

sub C1  
B6  
13. (Twice Amended) A method of treatment of a platelet aggregation disorder which comprises administering to a patient suffering from such a disorder a therapeutically effective amount of a compound according to Claim 1.

Claim 14, line 1, insert --as defined in claim 1-- after "(I)";

line 20, delete "• converting one or more functional groups into a further functional groups".

Please add the following new claims:

*C* ~~12~~ 15. A method of treatment ~~or prevention~~ of a condition selected from the group consisting of myocardial infarction, thrombotic stroke, transient ischaemic attack, peripheral vascular disease and angina, which comprises administering to a patient in need of such treatment ~~or prevention~~ an effective amount of a compound according to claim 1.

~~13~~ 16. A method according to claim ~~15~~ <sup>12</sup>, wherein the condition is angina.--